RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Nestor Gonzalez-Cadavid to Cyclic Nucleotide Phosphodiesterases, Type 5

This is a "connection" page, showing publications Nestor Gonzalez-Cadavid has written about Cyclic Nucleotide Phosphodiesterases, Type 5.
  1. Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010 Apr; 7(4):215-21.
    View in: PubMed
    Score: 0.365
  2. Rambhatla A, Kovanecz I, Ferrini M, Gonzalez-Cadavid NF, Rajfer J. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review. Int J Impot Res. 2008 Jan-Feb; 20(1):30-4.
    View in: PubMed
    Score: 0.076
  3. Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Davila HH, Rajfer J, Gonzalez-Cadavid NF. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod. 2007 May; 76(5):915-23.
    View in: PubMed
    Score: 0.074
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support